SPRO IVBIY innovent Biologics and Spero Therapeutics announce exclusive license for ibi355 (sp001), a phase 2-ready third-generation anti-cd
SPRO IVBIY innovent Biologics and Spero Therapeutics announce exclusive license for ibi355 (sp001), a phase 2-ready third-generation anti-cd40l antibody Innovent Biologics - Spero receives exclusive global rights to ibi355 excluding greater China - To receive payments totaling about $1.1B plus tiered royalties - Spero to initiate phase 2 trial for ibi355 in igg4-rd in Q2 2027 - To initiate phase 2 trial for sjögren's disease in China by early 2027
SPRO IVBIY innovent Biologics and Spero Therapeutics announce exclusive license for ibi355 (sp001), a phase 2-ready third-generation anti-cd40l antibody Innovent Biologics - Spero receives exclusive global rights to ibi355 excluding greater China - To receive payments totaling about $1.1B plus tiered royalties - Spero to initiate phase 2 trial for ibi355 in igg4-rd in Q2 2027 - To initiate phase 2 trial for sjögren's disease in China by early 2027